Can Women Take Semaglutide? Safety, Dosing & What to Expect

Can women take semaglutide? The short answer is yes — semaglutide is FDA-approved for weight management in adults, regardless of sex, and women make up a significant proportion of GLP-1 patients in clinical trials and real-world use. However, there are important considerations around hormonal health, fertility, and pregnancy that every woman should understand before starting treatment.

FDA Approval and Who Qualifies

Semaglutide (brand name Wegovy at the 2.4 mg dose) received FDA approval for chronic weight management in 2021. The approval applies to adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as type 2 diabetes, high blood pressure, or high cholesterol. These eligibility criteria apply equally to men and women.

Women were well-represented in the large clinical trials that led to semaglutide's approval, and the data confirmed robust weight loss outcomes across sexes. There is no clinical evidence that semaglutide is less safe or less effective in women than in men.

Weight Loss Outcomes in Women

Clinical trial data for semaglutide at the weight loss dose showed average reductions in body weight of approximately 15% over 68 weeks compared to placebo. Women in these trials experienced meaningful weight loss that translated to real-world improvements in energy, mobility, blood sugar control, and cardiovascular risk markers.

Individual results vary based on starting weight, adherence to the dosing schedule, dietary habits, physical activity, and metabolic factors. Some women find that weight loss plateaus at certain points, which is a known pattern with GLP-1 therapy — not a sign that the medication has stopped working. Your provider can adjust your protocol if progress stalls.

Semaglutide and PCOS

Polycystic ovary syndrome (PCOS) is one of the most common hormonal conditions in women of reproductive age, affecting up to 10–15% of women globally. PCOS is closely linked to insulin resistance and excess body weight, which is why many women with PCOS find it especially difficult to lose weight through diet and exercise alone.

Emerging research and clinical experience suggest that semaglutide may offer particular benefits for women with PCOS:

Weight loss itself improves insulin sensitivity and hormonal balance in PCOS
Reduced insulin levels can lower androgen production, helping with symptoms like excess hair growth and acne
Some women with PCOS report more regular menstrual cycles after losing weight on GLP-1 therapy
Improved metabolic markers (blood sugar, cholesterol, blood pressure) are well-documented with semaglutide use

If you have PCOS, discuss this with your Truventa provider — it may actually strengthen your case for treatment eligibility if your BMI is in the 27–29.9 range.

Hormonal Interactions to Know About

Semaglutide does not directly affect sex hormones like estrogen or progesterone. However, weight loss itself causes hormonal changes, and these can be significant. As body fat decreases, estrogen levels may shift (since fat tissue produces estrogen), and some women notice changes in their menstrual cycle — including irregular periods early in treatment. This is generally temporary and not a cause for concern, but it's worth monitoring.

For women on hormonal contraceptives, there is a theoretical consideration: semaglutide slows gastric emptying, which may theoretically affect the absorption of oral contraceptive pills. Current prescribing guidance recommends considering a backup contraceptive method during the first 4 weeks of semaglutide treatment and for 4 weeks after any dose increase, as these are the periods when gastric emptying changes are most pronounced. Discuss this with both your Truventa provider and your OB-GYN.

Pregnancy and Fertility Considerations

This is the most critical safety consideration for women taking semaglutide. Semaglutide is contraindicated during pregnancy. Animal studies have shown adverse effects on fetal development at doses used in clinical settings, and there is not yet sufficient human safety data to establish a safe use profile in pregnancy.

Key guidelines for women of reproductive age:

Use effective contraception while taking semaglutide
Stop semaglutide at least 2 months before attempting to conceive (the medication has a long half-life and takes time to clear the body)
If you become pregnant while on semaglutide, stop the medication immediately and inform your obstetric provider
Semaglutide is also not recommended while breastfeeding

Importantly, some women become more fertile as they lose weight — particularly those with PCOS — so do not assume that irregular cycles or PCOS-related infertility make pregnancy impossible. Effective contraception remains essential throughout treatment.

Getting Started with Truventa

Truventa's licensed providers have experience working with women across a wide range of health backgrounds, including those managing PCOS, hormonal imbalances, perimenopause, and other conditions that intersect with weight. Your intake evaluation will cover your full health picture so your provider can recommend the most appropriate GLP-1 protocol and flag any individualized considerations.

We're available in all 50 states, and the entire process — from consultation to prescription — happens online, on your schedule.

Ready to get started? Consult with a Truventa provider today →

This article is for informational purposes only and does not constitute medical advice.